ADGI ADAGIO THERAPEUTICS INC

Invivyd to Participate at the Jefferies Global Healthcare Conference

Invivyd to Participate at the Jefferies Global Healthcare Conference

WALTHAM, Mass., June 03, 2024 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD), a biopharmaceutical company devoted to delivering protection from serious viral infectious diseases, today announced that its management team is scheduled to participate in a fireside chat at the Jefferies Global Healthcare Conference on Thursday, June 6, 2024 at 3:00 p.m. ET in New York, NY.

In addition to the fireside chat, the management team will host investor meetings at the conference. Investors participating in the conference who are interested in meeting with Invivyd management should contact their Jefferies representative.

A live webcast of the fireside chat will be available in the investor section of the company's website at and will be archived for approximately 30 days following the presentation.

About Invivyd

Invivyd, Inc. (Nasdaq: IVVD) is a biopharmaceutical company devoted to delivering protection from serious viral infectious diseases, beginning with SARS-CoV-2. The company’s proprietary INVYMAB™ platform approach combines state-of-the-art viral surveillance and predictive modeling with advanced antibody engineering. INVYMAB is designed to facilitate the rapid, serial generation of new monoclonal antibodies (mAbs) to address evolving viral threats. In March 2024, Invivyd received emergency use authorization (EUA) from the U.S. FDA for its first mAb in a planned series of innovative antibody candidates. Visit to learn more.

Contacts:

Media Relations

(781) 208-0160

Investor Relations

(781) 208-0160



EN
03/06/2024

Underlying

ADGIADAGIO THERAPEUTICS INC

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on ADAGIO THERAPEUTICS INC

 PRESS RELEASE
Free
ADGI ADAGIO THERAPEU...

Invivyd and Leading Researchers Form SPEAR (Spike Protein Elimination ...

Invivyd and Leading Researchers Form SPEAR (Spike Protein Elimination and Recovery) Study Group to Assess the Effects of Monoclonal Antibody Therapy for Long COVID and COVID-19 Post-Vaccination Syndrome SPEAR Study Group initiated following multiple, independent reports of substantial clinical benefit associated with PEMGARDA® (pemivibart) therapy among people with Long COVID SPEAR Study Group collaborators Drs. Michael Peluso, Amy Proal, and David Putrino are key thought leaders in the clinical and translational biology of Long COVID and Post-Vaccination SyndromeInitial SPEAR clinical effo...

July 2, 2025 1 EN
 PRESS RELEASE
Free
ADGI ADAGIO THERAPEU...

Invivyd Announces Positive Full Phase 1/2 Clinical Data for VYD2311, a...

Invivyd Announces Positive Full Phase 1/2 Clinical Data for VYD2311, a Next Generation COVID-19 Monoclonal Antibody for Potential Use as a Non-Vaccine Preventative and for Treatment of Active Infection Attractive safety profile demonstrated across all dosing cohorts and routes of administration (IV, SC, and IM); all reported adverse events (AEs) deemed unrelated or classified as mild to moderate and largely related to injection site and infusion reactions with no serious or severe adverse events observedFollowing a single dose, serum concentrations of VYD2311 remained high at six months wit...

June 26, 2025 1 EN
 PRESS RELEASE
Free
ADGI ADAGIO THERAPEU...

Invivyd Announces Publication of Landmark CANOPY Phase 3 PEMGARDA® (pe...

Invivyd Announces Publication of Landmark CANOPY Phase 3 PEMGARDA® (pemivibart) Clinical Trial; Results Underscore Strong Efficacy of Monoclonal Antibodies in Preventing COVID-19 in a Modern U.S. Population Against Relevant, Immune-Evasive SARS-CoV-2 Virus CANOPY assessed pemivibart safety and tolerability, antiviral immunobridging, and exploratory efficacy against COVID-19, and is the only clinical trial of an authorized or approved COVID-19 monoclonal antibody or vaccine with placebo-controlled clinical efficacy data in a contemporary, seropositive U.S. population and facing modern, immun...

May 27, 2025 1 EN
 PRESS RELEASE
Free
ADGI ADAGIO THERAPEU...

Invivyd Announces Inclusion of PEMGARDA® (pemivibart) in National Comp...

Invivyd Announces Inclusion of PEMGARDA® (pemivibart) in National Comprehensive Cancer Network® (NCCN®) Clinical Practice Guidelines in Oncology for B-Cell Lymphomas WALTHAM, Mass., May 23, 2025 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD), today announced that PEMGARDA® (pemivibart), its investigational monoclonal antibody, has been added to the National Comprehensive Cancer Network® (NCCN®) Clinical Practice Guidelines in Oncology for B-Cell Lymphomas. NCCN joins the Infectious Disease Society of America (IDSA) that updated its COVID-19 guidelines in August 2024 to recommend the use...

May 23, 2025 1 EN
 PRESS RELEASE
Free
ADGI ADAGIO THERAPEU...

Invivyd Commends FDA Focus on Contemporary Evidence In Evaluating Medi...

Invivyd Commends FDA Focus on Contemporary Evidence In Evaluating Medical Interventions To Prevent COVID-19 FDA acknowledges that the benefit of repeat doses of COVID-19 vaccine boosters for Americans is uncertain; the updated regulatory framework for COVID-19 vaccines articulated by the Agency generally aligns with recent Invivyd Citizen Petition requestsIn contrast to vaccine boosters, monoclonal antibody (mAb) therapies, including pemivibart, underwent contemporary randomized, placebo-controlled trials to evaluate safety, immunogenicity, and exploratory efficacy in relevant, modern Ameri...

May 21, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch